Orthotopic Liver Transplantation Using a Living Donor
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00152607|
Recruitment Status : Terminated (Poor accrual)
First Posted : September 9, 2005
Last Update Posted : September 27, 2013
The purpose of this study is to:
determine the safety of donor right hepatic lobectomy as a procedure to provide a liver graft for living donor liver transplantation.
study the regeneration of liver tissue by volumetric testing for both donor and recipient.
assess if graft and patient survival with living donor transplantation is comparable to that of cadaveric donor transplantation.
|Condition or disease||Intervention/treatment||Phase|
|Liver Disease Liver Neoplasms||Procedure: donor right hepatic lobectomy||Phase 4|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Orthotopic Liver Transplantation Using a Living Donor Into An Adult Recipient|
|Study Start Date :||April 2000|
|Actual Primary Completion Date :||September 2006|
|Actual Study Completion Date :||September 2006|
- The primary outcome for donors in this study will be the determination of whether right hepatic lobectomy is a safe procedure for the donor as measured by survival, the incidence of surgical complications, liver function and regeneration studies. [ Time Frame: post transplant ]
- The primary outcome for recipients will be the assessment of patient and graft survival. Comparison to results of contemporaneous, non-randomized cadaver donor transplants will be made. [ Time Frame: post transplant ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00152607
|United States, Illinois|
|The University of Chicago Hospitals|
|Chicago, Illinois, United States, 60637|
|Principal Investigator:||J. Michael Millis, MD||The University of Chicago Hospitals|